AAM
JAZZ icon

Augustine Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Augustine Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,591
Closed -$210K – 118
2025
Q3 		$210K Buy
+1,591
New +$191K 0.04% 108

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Augustine Asset Management's JAZZ Position: Q4 2025 in Review

Augustine Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 1,591 shares — an estimated $210K sold.

Augustine Asset Management first reported a position in JAZZ in Q3 2025 and held it in 1 quarter. The position peaked at $210K in Q3 2025. 574 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Augustine Asset Management reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Augustine Asset Management sold 1,591 Jazz Pharmaceuticals shares in Q4 2025, an estimated $210K.
  • Augustine Asset Management first reported a position in Jazz Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Augustine Asset Management's Jazz Pharmaceuticals position peaked at $210K in Q3 2025.
  • 574 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Augustine Asset Management's 13F filing for Q4 2025, filed 16 Jan 2026.